

Department of Health & Human Services
Centers for Medicare & Medicaid Services
7500 Security Boulevard,
Baltimore, Maryland 21244



June 28, 2023

TO: ET3 Model Participants

SUBJECT: Notice of Termination of the Emergency Triage, Treat, and Transport Model

Thank you for your continued efforts and commitment to the Emergency Triage, Treat, and Transport (ET3) Model.

After careful consideration, the Centers for Medicare & Medicaid Services (CMS) has decided to end the ET3 Model (the “Model”) early, on December 31, 2023, which is two years prior to the ET3 Model Participation Agreement’s (the “Agreement”) original Performance Period end date.

Article 19.3(b) of the Agreement provides that CMS may immediately or with advance notice terminate the Agreement by promptly notifying the Participant, in writing, of the effective date of the termination and the reason for such termination. CMS may terminate the Agreement if CMS determines in its sole discretion that CMS no longer has the funds to support the Model or that continuing the Model is no longer in the public interest.

CMS has determined that it is in the public interest to end the ET3 Model. CMS made this determination based on a number of factors, including the current number of interventions. Current and projected number of interventions are lower than the number anticipated when the Model was designed. This affects the cost of operating the Model relative to its expected benefits, the ability of CMS to conduct a robust quantitative evaluation of the Model’s impact, and the Model’s ability to achieve the estimated Medicare savings in the Model’s design. For these reasons, CMS has determined that it is not in the public interest to test the Model in Performance Year 4 (i.e., Calendar Year 2024) through Performance Year 5 (i.e., Calendar Year 2025) and has good cause to unilaterally amend the Agreement to modify its Performance Period.

As a result of this decision, CMS intends to release an amendment to the Agreement within 30 days of this notice to modify the Model performance period. Article 21.4 of the Agreement provides that CMS may unilaterally amend the Agreement or any Appendix thereto as specified in the Agreement, including its Appendices, or for good cause or as necessary to comply with applicable federal or State law, regulatory requirements, accreditation standards or licensing guidelines or rules.

This decision does not affect Model Participants’ participation in the Model through December 31, 2023, the ability to bill for ET3 interventions with a date of service through December 31, 2023, or the ability to receive performance-based payments. In addition, this does not impact Participants’ ability to apply for any subsequent or future models. If you have any questions, please email ET3Model@cms.hhs.gov.

Thank you for your participation in the ET3 Model.

Sincerely,

A handwritten signature in black ink that reads "Arrah Tabe-Bedward". The signature is written in a cursive, flowing style.

Arrah Tabe-Bedward, Deputy Director
Center for Medicare and Medicaid Innovation
Centers for Medicare & Medicaid Services